BI 473494
Alternative Names: BI-473494Latest Information Update: 03 Dec 2018
At a glance
- Originator Zealand Pharma
- Developer Boehringer Ingelheim
- Class Obesity therapies
- Mechanism of Action Islet amyloid polypeptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 20 Nov 2018 Boehringer Ingelheim terminates a phase I trial in Healthy volunteers in Germany, for business reasons (SC) (NCT03195088)
- 15 Nov 2018 Discontinued - Phase-I for Obesity (In volunteers) in Germany (SC)
- 06 Nov 2017 Boehringer Ingelheim suspends patient enrolment in a phase I trial due to risk-benefit profile being re-evaluated in Healthy volunteers in Germany (SC) (NCT03195088)